Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : Italy to take legal action on COVID vaccine delays to get doses

01/24/2021 | 10:11am EST

MILAN, Jan 24 (Reuters) - Italy will take legal action and step up pressure in Brussels against Pfizer Inc and AstraZeneca over delays in deliveries of COVID-19 vaccines with a view to securing agreed supplies, Foreign Minister Luigi Di Maio said on Sunday.

The aim was to get the companies to meet the vaccine volumes they had promised and not to seek compensation, Di Maio said on RAI state television.

"This is a European contract that Pfizer and AstraZeneca are not respecting and so for this reason we will take legal action... We are working so our vaccine plan programme does not change," he said.

Pfizer said last week it was temporarily slowing supplies to Europe to make manufacturing changes that would boost output. On Friday, AstraZeneca said initial deliveries to the region will fall short because of a production problem.

Asked why he thought the pharmaceutical companies had been forced to announce reductions, Di Maio said he believed they had simply bitten off more than they could chew.

"We are activating all channels so the EU Commission does all it can to make these gentlemen respect their contracts," he said.

No one was immediately available to comment at Pfizer in Italy. AstraZeneca did not immediately reply to an email and voice message.

Also on Sunday European Council President Charles Michel said the EU would use legal means to ensure pharmaceutical companies respect supply contracts for COVID-19 vaccines.

"We plan to make the pharmaceutical companies respect the contracts they have signed ... by using the legal means at our disposal," Michel said on Europe 1 radio.

Sky Italia TV cited Pfizer on Sunday as saying the cuts, to the number of vials delivered and not the number of doses, had been due to work to increase capacity at a Belgian plant.

Supplies would return to normal as of next week, Sky cited Pfizer as saying.

On Saturday Italian Prime Minister Giuseppe Conte said the delays in vaccine supplies were "unacceptable" and amounted to a serious breach of contractual obligations, adding that Italy would use all available legal tools.

Speaking on Italian TV on Sunday Italy's Deputy Health Minister Pierpaolo Sileri said the cut in supplies announced by Pfizer and AstraZeneca would put back vaccination of the over-80s in Italy by about four weeks and the rest of the population by about 6-8 weeks.

"This kind of delay affects the whole of Europe and a good part of the world but I am confident the delay can be made up for further down the road," he said.

Italy was the first Western country to be hit by the virus last March and has registered 85,461 deaths so far, the second-highest toll in Europe after Britain and the sixth-highest in the world. (Reporting by Stephen Jewkes; Editing by Edmund Blair and Philippa Fletcher)

© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.93% 6945 Delayed Quote.-5.17%
PFIZER INC. -0.98% 33.49 Delayed Quote.-8.12%
All news about ASTRAZENECA PLC
07:07aHungarian PM receives Chinese vaccine as govt ramps up rollout
05:12aASTRAZENECA : German states call for unused AstraZeneca vaccine to be given to y..
02/27ASTRAZENECA : Thailand starts COVID-19 vaccination campaign
02/27J&J Covid-19 Vaccine Authorized for Use in U.S. -- 4th Update
02/27J&J Covid-19 Vaccine Authorized for Use in U.S. -- 3rd Update
02/27J&J Covid-19 Vaccine Authorized for Use in U.S. -- 2nd Update
02/27J&J Covid-19 Vaccine Authorized for Use in U.S. -- Update
02/27ASTRAZENECA : U.S. authorizes J&J's COVID-19 vaccine, making it third available
02/27J&J Covid-19 Vaccine Authorized for Use in U.S.
02/27FACTBOX-Johnson & Johnson's COVID-19 vaccine authorized in U.S.
More news
Financials (USD)
Sales 2021 30 828 M - -
Net income 2021 4 681 M - -
Net Debt 2021 12 157 M - -
P/E ratio 2021 26,8x
Yield 2021 2,95%
Capitalization 127 B 127 B -
EV / Sales 2021 4,51x
EV / Sales 2022 3,82x
Nbr of Employees 76 100
Free-Float 95,8%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Average target price 128,91 $
Last Close Price 96,76 $
Spread / Highest target 62,4%
Spread / Average Target 33,2%
Spread / Lowest Target -6,71%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC-5.17%126 967
JOHNSON & JOHNSON0.69%416 541
ROCHE HOLDING AG-3.58%280 845
NOVARTIS AG-6.53%194 250
ABBVIE INC.0.55%190 256
PFIZER INC.-8.12%186 852